Frontlight ResearchEarly access
Spinal muscular atrophy trials in Japan
2 of 4 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
- Where
- Toyonaka
- Age
- 15 years to 60 years
- People
- 90 worldwide
- Run by
- Biogen
See details and how to joinNCT07444476 - Phase 3Taking peopleA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- Where
- Tokyo
- Age
- 0 days to 42 days
- People
- 30 worldwide
- Run by
- Biogen
See details and how to joinNCT07221669 · EU 2025-524054-34-00